End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

被引：0
|
作者：
Shah, Bijal D.
Bishop, Michael Russell
Oluwole, Olalekan O.
Logan, Aaron
Baer, Maria R.
Donnellan, William Bruce
Carr-O'Dwyer, Kristen Marie
Holmes, Houston
Arellano, Martha Lucia
Ghobadi, Armin
Pagel, John M.
Lin, Yi
Cassaday, Ryan Daniel
Park, Jae Hong
Mardiros, Armen
Shen, Tong
Goyal, Lovely
Vezan, Remus
Jain, Rajul K.
Wierda, William G.
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA
[5] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA
[6] Sarah Cannon Res Inst, Nashville, TN USA
[7] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[8] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[9] Winship Canc Inst, Atlanta, GA USA
[10] Washington Univ, Sch Med, St Louis, MO USA
[11] Siteman Canc Ctr, St Louis, MO USA
[12] Swedish Canc Inst, Seattle, WA USA
[13] Mayo Clin, Rochester, MN USA
[14] Univ Washington, Sch Med, Seattle, WA USA
[15] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[17] Kite, Santa Monica, CA USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7006
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Preliminary results of phase I/II study of SENL-B19 chimeric antigen receptor T cell therapy in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r-ALL)
    Ma, F.
    Li, J.
    Ren, J.
    Zhang, X.
    Wang, F.
    Guo, X.
    Zhang, J.
    Wang, D.
    Liu, Q.
    Luo, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
    Wayne, Alan S.
    Van Huynh, Van
    Hijiya, Nobuko
    Rouce, Rayne H.
    Brown, Patrick A.
    Krueger, Joerg
    Kitko, Carrie L.
    Dela Ziga, Edward
    Hermiston, Michelle L.
    Richards, Michael K.
    Baruchel, Andre
    Schuberth, Petra C.
    Rossi, John
    Zhou, Lang
    Goyal, Lovely
    Jain, Rajul
    Vezan, Remus
    Masouleh, Behzad Kharabi
    Lee, Daniel W.
    HAEMATOLOGICA, 2023, 108 (03) : 747 - 760
  • [33] KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
    Shah, Bijal D.
    Ghobadi, Armin
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Boissel, Nicolas
    Cassaday, Ryan D.
    Leguay, Thibaut
    Bishop, Michael R.
    Topp, Max S.
    Tzachanis, Dimitrios
    O'Dwyer, Kristen M.
    Arellano, Martha L.
    Lin, Yi
    Baer, Maria R.
    Schiller, Gary J.
    Park, Jae H.
    Subklewe, Marion
    Abedi, Mehrdad
    Minnema, Monique C.
    Wierda, William G.
    DeAngelo, Daniel J.
    Stiff, Patrick
    Jeyakumar, Deepa
    Feng, Chaoling
    Dong, Jinghui
    Shen, Tong
    Milletti, Francesca
    Rossi, John M.
    Vezan, Remus
    Masouleh, Behzad Kharabi
    Houot, Roch
    LANCET, 2021, 398 (10299): : 491 - 502
  • [34] Preliminary results of novel safety interventions in adult patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in the ZUMA-3 Trial
    Shah, B.
    Stock, W.
    Wierda, W.
    Topp, M.
    Kersten, M. J.
    Houot, R.
    Boissel, N.
    Holmes, H. E.
    Schiller, G. J.
    Mardiros, A.
    Rossi, J.
    Jiang, Y.
    Shen, T.
    Aycock, J.
    Stout, S.
    Wiezorek, J.
    Jain, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
    Shah, Bijal D.
    Ghobadi, Armin
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Boissel, Nicolas
    Cassaday, Ryan D.
    Leguay, Thibaut
    Bishop, Michael R.
    Topp, Max S.
    Tzachanis, Dimitrios
    O'Dwyer, Kristen M.
    Arellano, Martha L.
    Lin, Yi
    Baer, Maria R.
    Schiller, Gary J.
    Park, Jae H.
    Subklewe, Marion
    Abedi, Mehrdad
    Minnema, Monique C.
    Wierda, William G.
    DeAngelo, Daniel J.
    Stiff, Patrick
    Jeyakumar, Deepa
    Dong, Jinghui
    Adhikary, Sabina
    Zhou, Lang
    Schuberth, Petra C.
    Faghmous, Imi
    Masouleh, Behzad Kharabi
    Houot, Roch
    BLOOD, 2022, 140 : 3158 - 3161
  • [36] ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
    Wayne, Alan S.
    Sender, Leonard S.
    Lee, Daniel Warnell
    Handgretinger, Rupert
    Brown, Patrick A.
    Jiang, Yizhou
    Navale, Lynn
    Stout, Shanna
    Aycock, Jeff
    Wiezorek, Jeffrey S.
    Jain, Rajul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
    Locke, Frederick L.
    Neelapu, Sattva S.
    Bartlett, Nancy L.
    Siddiqi, Tanya
    Chavez, Julio C.
    Hosing, Chitra M.
    Ghobadi, Armin
    Budde, Lihua E.
    Bot, Adrian
    Rossi, John M.
    Jiang, Yizhou
    Xue, Allen X.
    Elias, Meg
    Aycock, Jeff
    Wiezorek, Jeff
    Go, William Y.
    MOLECULAR THERAPY, 2017, 25 (01) : 285 - 295
  • [38] HEALTH-RELATED QUALITY OF LIFE AMONG REFRACTORY/RELAPSED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH KTE-X19: PHASE 2 RESULTS FROM ZUMA-3 TRIAL
    Shah, B. D.
    Solem, C.
    Feng, C.
    Maglinte, G. A.
    Wang, W. J.
    Shen, T.
    Masouleh, B. K.
    Houot, R.
    VALUE IN HEALTH, 2022, 25 (01) : S238 - S238
  • [39] Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
    Gu, Runxia
    Liu, Fang
    Zou, Dehui
    Xu, Yingxi
    Lu, Yang
    Liu, Bingcheng
    Liu, Wei
    Chen, Xiaojuan
    Liu, Kaiqi
    Guo, Ye
    Gong, Xiaoyuan
    Lv, Rui
    Chen, Xia
    Zhou, Chunlin
    Zhong, Mengjun
    Wang, Huijun
    Wei, Hui
    Mi, Yingchang
    Qiu, Lugui
    Lv, Lulu
    Wang, Min
    Wang, Ying
    Zhu, Xiaofan
    Wang, Jianxiang
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [40] Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients
    Wang, Ying
    Li, Hujun
    Song, Xuguang
    Qi, Kunming
    Cheng, Hai
    Cao, Jiang
    Shi, Ming
    Yan, Zhiling
    Jing, Guangjun
    Pan, Bin
    Sang, Wei
    Wang, Xiangmin
    Zhao, Kai
    Chen, Chong
    Chen, Wei
    Zheng, Junnian
    Li, Zhenyu
    Xu, Kailin
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (02) : 250 - 258
12345